ClinicalTrials.gov
public full text
Public Domain
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC#140986
- Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)#245515
- X-ray and Radio Analysis of Abell 1644: Constraints on Cluster Dynamics#1128504
- The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC#353259
- Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination#979820
Record · ID 414502
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive